HeartWare Points To Less Acute Patients As One Key To HVAD Success
This article was originally published in The Gray Sheet
Executive Summary
As HeartWare awaits an approval decision for its first left ventricular assist device, the company says it is continuing to advance its pipeline and push forward with a longer-term strategy to maximize the treatable population for the product.
You may also be interested in...
FDA Holds Up HeartWare LVAD Trial In Less Advanced Heart Failure Patients
Investigators for the REVIVE-IT pilot study received a second deficiency letter from FDA May 11; researchers say they continue to work with the agency to move forward on the 100-patient, randomized trial.
News In Brief
Novartis buys Genoptix
HeartMate Meets Its Match? HeartWare VAD Data Has Good Showing At AHA
Thoratec's days monopolizing the ventricular assist device market with its HeartMate VAD technology appear to be numbered. That's the consensus out of last week's American Heart Association annual meeting, where upstart HeartWare reported impressive results for its next-generation VAD in late-stage heart failure patients waiting for a transplant.